Progyny, Inc. (PGNY) Form 10-Q — Nov 5, 2026
Progyny (PGNY) reported strong Q3 2026 results in its 10-Q: revenue of $341.3 million rose 9% year over year, while net income nearly doubled to $26.3 million from $13.9 million, with diluted EPS of $0.32 versus $0.15 a year ago. Gross margin expanded 130 basis points to 24.5%, driven by care management efficiencies and lower stock-based compensation after the November 2021 retention grant fully vested. The company grew to 607 clients and 7.155 million covered lives, up from 555 clients and 6.689 million members at year-end 2025.
Key figures
- Eps
- 0.32
- Revenue
- 341254000
- Net Income
- 26252000
- Revenue Yoy
- 9%
- Total Assets
- 675793000
- Cash Position
- 116820000
- Shares Outstanding
- 73647334
- Clients
- 607
- Buyback cost
- 230900000
- Art cycles q3
- 16723
- Covered lives
- 7155000
- Gross margin q3
- 24.5%
- Buyback avg price
- 23.83
- Buyback remaining
- 85800000
- Revolver capacity
- 200000000
- Adjusted ebitda q3
- 58439000
- Buyback shares ytd
- 9681135
- Nine month revenue
- 1020269000
- Q3 2025 eps diluted
- $0.15
- Q3 2026 eps diluted
- $0.32
- Nine month net income
- 78536000
- Adjusted ebitda nine months
- 177126000
- Operating cash flow nine months
- 152979000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.